MYGN vs. BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, NVAX, GERN, and RGLS
Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Myriad Genetics vs. Its Competitors
Myriad Genetics (NASDAQ:MYGN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.
Myriad Genetics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
In the previous week, BioCryst Pharmaceuticals had 15 more articles in the media than Myriad Genetics. MarketBeat recorded 16 mentions for BioCryst Pharmaceuticals and 1 mentions for Myriad Genetics. BioCryst Pharmaceuticals' average media sentiment score of 0.53 beat Myriad Genetics' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
BioCryst Pharmaceuticals has a net margin of -10.62% compared to Myriad Genetics' net margin of -12.20%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Myriad Genetics' return on equity.
99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 2.1% of Myriad Genetics shares are owned by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
BioCryst Pharmaceuticals has lower revenue, but higher earnings than Myriad Genetics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
Myriad Genetics presently has a consensus price target of $14.38, suggesting a potential upside of 155.73%. BioCryst Pharmaceuticals has a consensus price target of $16.70, suggesting a potential upside of 81.62%. Given Myriad Genetics' higher probable upside, equities analysts clearly believe Myriad Genetics is more favorable than BioCryst Pharmaceuticals.
Summary
BioCryst Pharmaceuticals beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.
Get Myriad Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Myriad Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:MYGN) was last updated on 7/9/2025 by MarketBeat.com Staff
